This is a working overview of AOD-9604, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-20. Anything still debated is marked as such rather than presented as settled.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Cereulide 2-methyl-5-HT Alpha-Methyltryptamine Bufotenin Chlorophenylbiguanide Ibogaine Phenylbiguanide Quipazine RS-56812 – Potent and selective 5-HT3 partial agonist, 1000× selectivity over other serotonin receptors SR-57227 Varenicline YM-31636 S 21007 (SAR c.f. CGS-12066A)
It is often found growing amid normally colored death caps. It has been described, in 2004, as a distinct variety and includes what was termed A. verna var. tarda. The true A. verna fruits in spring and turns yellow with KOH solution, whereas A. phalloides never does.
=== Communities === Scabies is endemic in many developing countries, and it tends to be particularly prevalent in rural and remote areas. In such settings, community-wide control strategies are required to reduce the rate of disease, as treatment of only individuals is ineffective due to the high rate of reinfection. Large-scale mass drug administration strategies may be required where coordinated interventions aim to treat whole communities in one concerted effort. Although such strategies have shown to be able to reduce the burden of scabies in these kinds of communities, debate remains about the best strategy to adopt, including the choice of drug. The resources required to implement such large-scale interventions in a cost-effective and sustainable way are significant. Furthermore, since endemic scabies is largely restricted to poor and remote areas, it is a public health issue that has not attracted much attention from policymakers and international donors.
Sources: en.wikipedia.org
Zenobi-Wong works in the area of tissue engineering, in particular for cartilage regeneration. She develops functional biomaterials which mimic the extracellular matrix. The biofabrication techniques used to develop these materials include electrospinning, casting, two-photon polymerization and bioprinting. Zenobi-Wong holds four licensed patents in the fields of tissue engineering, tissue engineering techniques, and gene expression assays. She was one of the originators of the MSc Biomedical Engineering program at ETH Zürich, and developed several graduate level courses in tissue engineering and biomedical engineering. Zenobi-Wong currently serves as President of the Swiss Society for Biomaterials and Regenerative Medicine, and as secretary general of the International Society of Biofabrication. ETH Zürich Department of Health Sciences and Technology - Tissue Engineering and Biofabrication Group Marcy Zenobi-Wong publications indexed by Google Scholar
=== Other compounds === Actinium hydride was obtained by reduction of actinium trichloride with potassium at 300 °C (572 °F), and its structure was deduced by analogy with the corresponding LaH2 hydride. The source of hydrogen in the reaction was uncertain. Mixing monosodium phosphate (NaH2PO4) with a solution of actinium in hydrochloric acid yields white-colored actinium phosphate hemihydrate (AcPO4·0.5H2O), and heating actinium oxalate with hydrogen sulfide vapors at 1,400 °C (2,550 °F) for a few minutes results in a black actinium sulfide Ac2S3. It may be produced by acting with a mixture of hydrogen sulfide and carbon disulfide on actinium oxide at 1,000 °C (1,830 °F).
Alpha-glucosidase inhibitors are a class of diabetes drugs found in plants/herbs like cinnamon; however, they are technically not hypoglycemic agents because they do not have a direct effect on insulin secretion or sensitivity. These agents slow the digestion of starch in the small intestine, such that glucose from the starch enters the bloodstream at a slower rate, and can be matched more effectively by an impaired insulin response or sensitivity. The intake of a single dose before a meal containing complex carbohydrates clearly suppresses the glucose spike and may decrease the postprandial hyperglycemia (higher than 140 mg/dL; >7.8 mmol/L) in patients with type II diabetes. These agents are effective by themselves only in the earliest stages of impaired glucose tolerance, but can be helpful in combination with other agents in type 2 diabetes. Typical reductions in glycated hemoglobin (A1C) values are 0.5–1.0%.
Sources: en.wikipedia.org
Social prejudice against extreme shortness may reduce social and marital opportunities. Numerous studies have demonstrated reduced employment opportunities. Severe shortness is associated with lower income. Self-esteem may decline and family relationships may be affected. Extreme shortness (in the 60–90 cm or 2–3 feet range) can, if not accommodated for, interfere with activities of daily living, like driving or using countertops built for taller people. Other common attributes of dwarfism such as bowed knees and unusually short fingers can lead to back problems and difficulty in walking and handling objects. Children with dwarfism are particularly vulnerable to teasing and ridicule from classmates. Because dwarfism is relatively uncommon, children may feel isolated from their peers.
=== Segmental and molecular motions === In addition to providing static information on molecules by determining their 3D structures, one of the remarkable advantages of NMR over X-ray crystallography is that it can be used to obtain important dynamic information. This is due to the orientation dependence of the chemical-shift, dipole-coupling, or electric-quadrupole-coupling contributions to the instantaneous NMR frequency in an anisotropic molecular environment. When the molecule or segment containing the NMR-observed nucleus changes its orientation relative to the external field, the NMR frequency changes, which can result in changes in one- or two-dimensional spectra or in the relaxation times, depending on the correlation time and amplitude of the motion.
Neurosteroids such as dehydroepiandrosterone (DHEA) and allopregnanolone, which modulate neurotransmitter receptors in the brain. Bile acids such as taurocholic acid, which aid in lipid digestion and absorption in the intestine. Aminosteroid neuromuscular blocking agents (synthetic), such as pancuronium bromide, used in anesthesia to induce muscle relaxation. Steroidal antiandrogens (synthetic), such as cyproterone acetate, which block androgen receptors in hormone therapy. Steroidogenesis inhibitors (exogenous), such as alfatradiol, which suppress steroid synthesis for therapeutic purposes. Membrane sterols such as cholesterol (essential for cell membrane fluidity), ergosterol (a fungal membrane component), and various phytosterols (plant-derived sterols with cholesterol-lowering effects). Toxins such as steroidal saponins (plant defense compounds) and cardenolides/cardiac glycosides (which affect heart function). Steroids with an open-ring structure, known as secosteroids, include:
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.